Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16240875 | 0.89 | ALDH1A1 (0.38) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL5078447 | 0.79 | LMNA (0.46) | CYP3A4ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL1232253 | 0.79 | LMNA (0.46) | CYP3A4ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL28889391 | 0.79 | LMNA (0.46) | CYP3A4ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL5084405 | 0.77 | ALDH1A1 (0.44) | ALDH1A1HIF1ALMNAMAPTKMT2A | |
| SCHEMBL5084403 | 0.77 | ALDH1A1 (0.44) | ALDH1A1HIF1ALMNAMAPTKMT2A | |
| SCHEMBL28239003 | 0.77 | SLC1A5 (0.35) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Hydrochloric Acid SCHEMBL31375791 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HIF1ALMNAMAPTKMT2A | |
| SCHEMBL28374594 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HIF1ALMNAMAPTKMT2A | |
| SCHEMBL28709734 | 0.74 | PKM (0.37) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0415731-B1 | Novel entities for cancer therapy | WELLCOME FOUND (GB) | 2003-04-02 | — | — | EP | claimed |
| EP-0690129-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-03 | — | — | EP | claimed |
| EP-0657541-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| EP-0657539-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| EP-0657540-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| US-11214815-B2 | Nucleic acid Construct | IP2IPO INNOVATIONS LIMITED (GB) | 2022-01-04 | — | — | US | disclosed |
| US-10258676-B2 | Polypeptide vaccine | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-04-16 | — | — | US | disclosed |
| US-20150306196-A1 | POLYPEPTIDE VACCINE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-10-29 | — | — | US | disclosed |
| US-20150232878-A1 | Construct | IP2IPO INNOVATIONS LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-7977091-B2 | Eukaryotic layered vector initiation systems | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110052577-A1 | Antibodies | OXFORD BIOMEDICA (UK) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-7875259-B2 | Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders | D-GEN LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-0792366-A1 | ENZYME GENE THERAPY CATALYSING PRODRUG EXTRACELLULAR CONVERSION | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-09-03 | — | — | EP | disclosed |
| EP-0512002-B1 | CELL-SPECIFIC ENZYME-CONJUGATES FOR THE RELEASE OF TOXIC CYANIDE FROM CYANOGENIC PRODRUGS AT TARGET CELLS | IMP CANCER RES TECH (GB) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996016179-A1 | ENZYME GENE THERAPY CATALYSING PRODRUG EXTRACELLULAR CONVERSION | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| EP-0679094-A1 | COMPOUNDS FOR TARGETING | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994015644-A1 | COMPOUNDS FOR TARGETING | IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
| EP-0408546-B1 | IMPROVEMENTS RELATING TO DRUG DELIVERY SYSTEMS | CANCER RES CAMPAIGN TECH (GB) | 1994-04-27 | — | — | EP | disclosed |
| EP-0408546-A1 | IMPROVEMENTS RELATING TO DRUG DELIVERY SYSTEMS. | CANCER RES CAMPAIGN TECH (GB) | 1991-01-23 | — | — | EP | disclosed |
| WO-1988007378-A1 | IMPROVEMENTS RELATING TO DRUG DELIVERY SYSTEMS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1988-10-06 | — | — | WO | disclosed |